TY - JOUR T1 - Our results of stereotactic radiotherapy in advanced stage lung cancer patients JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P2720 AU - Ahmet Fatih Oruç AU - Naciye Özseker AU - Sule Karabulut Gül AU - Mihriban Koçak AU - Hazan Özyurt AU - Duygu Gedik AU - Emriye Algül AU - Özlem Malas Oruç AU - Alpaslan Mayadagli Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P2720.abstract N2 - Objective: To investigate our results of stereotactic body radiotherapy (SBRT) in advanced stage lung cancer patients.Methods: Twentyone patients underwent stereotactic body radiotherapy who admitted Dr. Lutfi Kirdar Kartal Training and Research Hospital between 2010-2013. All the patients were man and median age was 63 years.Thirteen patients were ECOG 1 and the eight of them were ECOG 2. Eighteen of the patients were nonsmall cell ca, two of them were small cell and one was mesenchymal tumor. Thirteen patients have been treated with radiotherapy before. Three of these patients were treated with boost treatment after the external radiotherapy, the other three of them were treated with raditherapy for the second primary field and seven of them were treated as a second line because of the progression after the external radiotherapy. The eight of the patients who were not treated with radiotherapy before underwent SBRT for palliative tretment. Tumors were central in 13 patients and peripheral in 8 patients. We used CK robotic radiosurgery system (Accuray,Sunnyvale,CA,USA). The patients were treated with SBRT to median of 32 Gy(12-45) in 2- 5 fractions.Results: The mean follow-up after SBRT was 15 months. The local recurrence-free survival was 17 months. No adverse effect has been reported.Conclusion: Stereotactic radiotherapy is useful for local control and palliation in advanced stage lung cancer. ER -